More importantly, the increased uptake of this radiopharmaceutical in PCa lesions compared with other PSMA-targeted tracers improves tumor-to-background ratios, making it easier to detect small PCa lesions [25,26,29]. The gene discussed is FOLH1; the disease is neoplasm.